Anaphylaxis

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.

Research suggests emergency department–discharged children rarely return within 7 days, questioning routine corticosteroid use for mild-to-moderate reactions.

In over 500 patients, a single dose of neffy achieved an 89% success rate, matching injection outcomes and supporting its use as a needle-free alternative.

A study shows that sex modifies HRQL outcomes in peanut OIT: males benefit most from active treatment, while females show strong placebo gains.

Cluster protocol VIT demonstrates high efficacy in children with venom allergies, showing low systemic reactions and strong protection against re-stings.

The basophil activation test shows the greatest accuracy in predicting allergic reactions to baked and fresh cow’s milk, reducing the need for oral food challenges in children.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

Study highlights risk factors and diagnostic accuracy for immediate-type local anesthetic allergy in children.

Study reveals 7 communication strategies clinicians can use to convey allergy risk and guide adrenaline auto-injector decisions in pediatric consultations.

MGH investigators confirmed the reliability of the Drug Allergy History Tool (DAHT), which outperformed EHR documentation in completeness.

Four allergens not on the FDA or EFSA food allergy list show high frequency in a recent study. Anaphylaxis induced by goat or sheep milk led to 2 deaths.

A discrete choice experiment revealed food allergy treatment preferences among adolescents, with efficacy ranking as the most important attribute.

Multicenter study finds most children with anaphylaxis can be safely discharged within 2 hours, with 4 hours for those with cardiovascular involvement.

A new advisory highlights cephalexin’s efficacy and low cross-reactivity risk, supporting its safe use in patients with penicillin allergy.

New research confirms that adrenaline is safe and effective for anaphylaxis, debunking myths.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

In this large study, oral berotralstat resulted in early and sustained reductions in HAE attack rates, offering a promising long-term prophylaxis option.

In a study of children with food allergy and atopic dermatitis, longer dupilumab use was associated with significantly lower food-specific IgE levels.

A 4.5 mm cut-off using the Skin Prick Automated Test showed comparable accuracy to the standard skin prick test in detecting birch pollen and house dust mite allergies.

This month in review spotlights 6 headlines, from the FDA approving sebetralsta for HAE to NICE Recommending Betula Verrucosa for Birch Tree Allergy.

An online course, AllergyAware, significantly improved school personnel’s ability to recognize and manage anaphylaxis.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

A new study showed that cashew-induced anaphylaxis mostly affects children under 5 years, often from tiny amounts that are under a teaspoon.